CD8A and neoplasm: In addition to targeting cancer cells, metformin has been shown to target immune cells in the tumor microenvironment, such as CD8+ T cell, regulatory cells (Tregs), MDSCs and tumor-associated macrophages (TAMs), which may contribute to the expression of anti-tumor activities [170].